Shots:
- The P-II/III study involves assessing of Troriluzole (qd, PO) vs PBO in 350 patients with mild to mod. AD for up to 48wks.
- The study missed its co-primary endpoints i.e. ADAS-cog & CDR-SB. The therapy also failed to beat PBO on the 2EPs of hippocampal volume assessed by MRI in the overall population
- A subgroup analysis of mild AD patients unveils that troriluzole exhibited a nonsignificant numerical difference of a potential benefit @48wks. on both the ADAS-cog and hippocampal volumetric MRI. Further, secondary & exploratory efficacy analyses and biomarker data including NfL, neurogranin, tau and amyloid are still pending and are expected in the coming mos.
Click here to read full press release/ article | Ref: Biohaven | Image: PR Newswire
The post Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease first appeared on PharmaShots.
